Document:

EX-10.21(d)

 Exhibit 10.21(d) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 Contract Amendment No. 3 

to the 
 Development and Supply
Agreement as of May 29, 2008 
 by and between 

ViewRay Incorporated 

with its registered seat in Beachwood, OH, USA 

— hereinafter referred to as “ViewRay” — 

and 
 Siemens AG 

Healthcare Sector 
 —
hereinafter referred to as “Siemens” — 
 — VIEWRAY and Siemens hereinafter referred to individually 

as “Party” or collectively as “Parties” — 

Preamble 
 The Parties have signed a
Development and Supply Agreement on May 29, 2008, as amended (the “2008 Agreement”) with the intention to do collaborate in the Development of combining MR imaging and Gamma Radio Therapy. In this Contract Amendment No. 3,
the Parties agree to make certain clarifications to the 2008 Agreement as described below. 
 Agreement 

1. Amendment to Article 2.3. Article 2.3 of the 2008 Agreement is hereby amended to read in full as follows: 

“2.3 SIEMENS will cause its wholly owned indirect U.S. subsidiary, Siemens Medical Solutions USA, Inc., to provide one or more System Engineers on-site at VIEWRAY to work with VIEWRAY on the MRI system hardware.” 
 2. Amendment to Article 2.4.
Article 2.4 of the 2008 Agreement is hereby amended to read in full as follows: 
 “2.4 SIEMENS will cause its wholly owned indirect U.S.
subsidiary, Siemens Medical Solutions USA, Inc. to provide one or more Applications Specialists on-site at VIEWRAY to work with VIEWRAY to support MRI sequence and application optimization in order to achieve real-time requirements.” 
 3. Amendment to Appendix 1 concerning reimbursement of certain Labor
costs. The second bulleted item on Appendix 1 to the 2008 Agreement is hereby amended to read as follows: 

	 	•	 	VIEWRAY agrees to reimburse Siemens Medical Solutions USA, Inc. for the costs associated with [***], including but not limited to the costs of: (1) [***] made available to VIEWRAY, (2) [***], (3) [***]
allowances, (4) [***] and (5) all [***], if necessary, associated with [***] in connection with SIEMENS obligation under this Agreement. Siemens Medical Solutions USA, Inc. shall issue an invoice on a quarterly basis meeting the
requirements of tax laws. Notwithstanding the foregoing, it is understood and agreed by the parties, that at all times during the term of this Agreement, the System Engineers and Application Specialists made available by SIEMENS to provide services
on site at VIEWRAY are employees of Siemens Medical Solutions USA, Inc.” 

 4. Duration: This Contract Amendment No. 3 shall
take effect on the date it is signed by both Parties. 
 5. Ratification: Except to the extent expressly amended by this Contract Amendment
No. 3, all of the clauses and conditions of the 2008 are hereby ratified and confirmed and shall remain valid in full force and effect. The term “Agreement”, as used in the 2008 Agreement, shall henceforth be deemed to be a reference
to the 2008 Agreement as amended by this Contract Amendment No. 3. 
 6. General: This Contract Amendment No. 3 may be executed in
counterparts, each of which will be deemed an original with all such counterparts together constituting one instrument. Capitalized terms used in this Contract Amendment No. 3 and not defined herein are used with the meanings ascribed to them
in the 2008 Agreement. 
 ViewRay Incorporated 
  

			
	Place, Date:
	 Oakwood Village, OH, USA 20 Jan 2011

	
	 /s/ Greg Ayers, M.D. Ph.D

		
	Name:	 	 Greg Ayers, M.D. Ph.D

		 	(Print)
	Title:	 	 Chief Executive Officer

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Siemens AG., 

Healthcare Sector 
  

					
	Place, Date:	  		  	
			
	 Erlangen, February 9th, 2011
	  		  	
			
	 iV. /s/ Holger Liebel
	  		  	 i.V. /s/ Christopher Zindel

			
	Name:	  		  	Name:
			
	 Holger Liebel
	  		  	 Dr. Christoph Zindel

	(Print)	  		  	(Print)
			
	Title:	  		  	Title:
			
	 CFO Magnetic Resonance
	  		  	 VP Marketing Magnetic Resonance

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.21(e)

 Exhibit 10.21(e) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 Contract Amendment No. 4 

to the 
 Development and Supply
Agreement as of May 29, 2008 
 by and between 

ViewRay Incorporated, 
 With
its registered seat in Oakwood Village, OH, USA 
 — hereinafter referred to as “VIEWRAY” — 

and 
 Siemens AG 

Healthcare Sector 
 With its
registered seat in Berlin and Munich 
 — hereinafter referred to as “Siemens” — 

— ViewRay and Siemens hereinafter referred to individually 

as “Party” or collectively as “Parties” — 

Preamble 
 The Parties entered into a Development and
Supply Agreement in May 2008, as amended by the Contract Amendment No. 1 that the Parties entered into as of December 1, 2009 and the Contract Amendment No. 2 that the Parties entered into as of May 4, 2010 (collectively, the
“Development and Supply Agreement”) with the intention to combine their know-how and experience for the purpose of forming a long-term business relationship for the supply of Magnetic Resonance Imaging (“MRI”) subsystems
(“COMPONENTS” for MRgRT systems to provide real-time beam-on imaging and targeting of tumors. In this Contract Amendment No. 4, the Parties agree on the following additions and changes to the Development and Supply Agreement: 

Article 1 
 The Parties recognize and agree that
PHASE 2 of the Business Relationship as described in Article 3 of the Development and Supply Agreement is completed, with the exception of [***]. 

Article 2 
  

	2.1	Now therefore, the Parties agree to enter PHASE 3 of the Business Relationship as described in Article 4 of the Development and Supply Agreement subject to the amendment set forth in Article 2.2 below.
Subject to the amendment set forth in Article 2.2 below, the Parties have made the determination that [***]. 

	2.2	The Parties agree that the milestones of PHASE 2 are modified to [***]. The Parties will [***]. 

Duration: This Contract Amendment No. 4 shall take effect on the date it is signed by both Parties. 

Ratification: Except to the extent expressly amended by this Contract Amendment No. 4 all of the clauses and conditions of the Development and
Supply Agreement are hereby ratified and confirmed and shall remain valid in full force and effect. The term “Agreement”, as used in the Development and Supply Agreement, shall henceforth be deemed to be a reference to the Development and
Supply Agreement as amended by this Contract Amendment No. 4. 
 General: This Contract Amendment No. 4 may be executed in counterparts,
each of which will be deemed a original with all such counterparts together constituting one instrument. Capitalized terms used in this Contract Amendment No. 4 and not defined herein are used with the meanings ascribed to them in the
Development and Supply Agreement. 
 [remainder of this page intentionally left blank] 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the parties have caused this Contract Amendment No. 4 to be executed on their behalf by
their duly authorized representatives. 
  

					
	ViewRay Incorporated	  	Siemens AG, Healthcare Sector
			
	Place, Date:	  	Place, Date:	  	
			
	 Oakwood, OH, USA 11 May 2012
	  	 Erlangen, 23 04 12
	  	
			
	 /s/ Gregory M. Ayers
	  	 i.V. /s/ Dr. Christoph Zindel
	  	 iV. /s/ Holger Liebel

			
	Name:	  	Name:	  	Name:
			
	 Gregory M. Ayers
	  	 Dr. Christoph Zindel
	  	 Holger Liebel

	(Print)	  	(Print)	  	(Print)
			
	Title:	  	Title:	  	Title:
			
	 Chief Executive Officer
	  	 VP MR Marketing
	  	 CFO Magnetic Resonance

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.21(f)

 Exhibit 10.21(f) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 Contract Amendment No. 5 

to the 
 Development and Supply
Agreement as of May 29, 2008 
 by and between 

ViewRay Incorporated, 

with its registered seat in Oakwood Village, OH, USA 

— hereinafter referred to as “Viewray” — 

and 
 Siemens AG 

Healthcare Sector 
 —
hereinafter referred to as “Siemens” — 
 — VIEWRAY and Siemens hereinafter referred to individually 

as “Party” or collectively as “Parties” — 

Preamble 
 The Parties have signed a
Development and Supply Agreement on May 29, 2008, as amended (the “2008 Agreement”) with the intention to collaborate in the development of combining MR imaging and gamma radiotherapy. In this Contract Amendment No. 5, the
Parties agree to make certain amendments to the 2008 Agreement as described below. 
 Agreement 

Article 1. Amendment to Article 1.1 of Annex 2 in Appendix 2 

The first three sentences of Article 1.1 of Annex 2 in Appendix 2 of the 2008 Agreement (the Supply Agreement) are hereby amended to read in
full as follows: 
 “1.1 SELLER will provide BUYER with a list of COMPONENTS, with their part number and part description, in a form similar to the
following list. 
 [***] 

 The components in the list may be updated from time to time with respect to model numbers, SELLER shall notify
the BUYER of any changes. BUYER is also allowed to request of SELLER to add other items onto the list, BUYER’S consent will not be unreasonably withheld. 

The prices for COMPONENTS shall be [***] (Incoterms 2000) including packaging. The valid prices for COMPONENTS shall be communicated separately by the SELLER
to the BUYER on or before the Effective Date of this Contract Amendment No. 5. The SELLER shall inform the BUYER giving at least [***] notice about price changes with new pricing becoming effective only after such notice period.” 

The Table at the end of Article 1.1 is deleted and replaced with a list of COMPONENTS, which will be provided on or before the Effective Date of this
Contract Amendment No. 5. 
 Article 2. Amendment to Article 1.2 of Annex 2 in Appendix 2 

Article 1.2 of Annex 2 in Appendix 2 of the 2008 Agreement (the Supply Agreement) is hereby amended to read in full as follows: 

“1.2 The price shall be net, fixed in US $. Any fiscal charges, taxes, etc., that arise shall be listed separately.” 

Article 3. Duration: 
 This Contract Amendment No. 5
shall take effect on the date it is signed by both Parties. 
 Article 4. Miscellaneous: 

4.1 Except to the extent expressly amended by this Contract Amendment No. 5, all of the clauses and conditions of the 2008 Agreement shall remain
unaffected. The term “Agreement”, as used in the 2008 Agreement, shall henceforth be deemed to be a reference to the 2008 Agreement as amended by this Contract Amendment No. 5. 

4.2 This Contract Amendment No. 5 may be executed in counterparts, each of which will be deemed an original with all such counterparts together
constituting one instrument. Capitalized terms used in this Contract Amendment No. 5 and not defined herein are used with the meanings ascribed to them in the 2008 Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	
	ViewRay Incorporated
	
	Place, Date:
	
	 Oakwood, OH, USA, 30 May 2012

	
	  

	
	Name: Greg Ayers, M.D. Ph.D.
	
	Title: Chief Executive Officer

 Siemens AG., 

Healthcare Sector 
  

					
	Place, Date:	 		  	
			
	 Erlangen, 04.05.12
	 		  	 Erlangen, 9.5.12

			
	 /s/ I.V. Zindel
	 		  	 /s/Holger Liebel

			
	Name:	 		  	Name:
			
	 Dr. Christoph Zindel
	 		  	 Holger Liebel

	(Print)	 		  	(Print)
			
	Title:	 		  	Title:
	      VP Marketing MR
	 		  	      CFO Magnetic Resonance

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Valid from 1.01.2011 to 1.01.2013 

[***] 

  
 [***] Two pages in this document
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]